Tumor-associated antigens on autologous renal cell carcinoma cells (RCC TAA)

Tumor-associated antigens (TAAs) on autologous renal cell carcinoma (RCC) cells refer to the unique set of proteins, glycoproteins, and glycolipids expressed by a specific patient's kidney tumor. These antigens serve as the basis for personalized immunotherapy, where the patient's own tumor material is used to create vaccines or prime dendritic cells to trigger a targeted immune response (Su et al., 2003, Cancer Res). By utilizing the full repertoire of autologous antigens, these therapies aim to address the high degree of intratumoral heterogeneity characteristic of RCC, potentially preventing the immune escape that often occurs with single-antigen targets (Amin et al., 2015, J Immunother Cancer). Drugs targeting these antigens, such as Rocapuldene-T and Vitespen, work by presenting these TAAs to the patient's T-cells, thereby inducing a polyclonal cytotoxic response against the cancer (Wood et al., 2008, Lancet). This approach is primarily investigated in the treatment of metastatic renal cell carcinoma to improve overall survival and provide a durable clinical benefit (Figlin et al., 2009, J Clin Oncol). However, the complexity of manufacturing personalized treatments and the variability of antigen expression across different tumor sites remain significant therapeutic challenges.

Other names

Autologous renal cell carcinoma antigensRCC tumor-associated antigensAutologous tumor lysate antigensPatient-specific RCC antigens

Active immunotherapy via the induction of a polyclonal T-cell response against patient-specific tumor antigens.